Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 µM) significantly protected rat PC12 cells against β-amyloid (Aβ 1-42 ) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPα) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPα was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 µM), suggesting that the effect is mediated via α-secretase activity. Rasagiline-induced sAPPα release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 µM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 µM) and GF109203X (2.5 µM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPα-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPα and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.
asagiline [N-propargyl-(1R)-aminoindan], a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinson drug (1) exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo (2) . The mechanism underlying the neuroprotection by rasagiline has been studied in dopaminergic SH-SY5Y and PC12 cells in culture against apoptosis induced by N-methyl (R) salsolinol, the peroxynitrite donor, SIN-1(N-morpholino-sydnonimine), 6-hyroxydopamine, and serum and nerve growth factor (NGF) withdrawn (3) (4) (5) (6) (7) (8) . We have previously shown that rasagiline and related propargylamines suppress apoptotic cell death cascade initiated by the mitochondria; they prevented preapoptotic decline in mitochondrial membrane potential (∆Ψm) due to permeability
In previous preliminary studies, we speculated that the propargylamine moiety of the antiAlzheimer drugs TV3326 and TV3279 might be pharmacologically responsible for MAPKdependent APP processing (17) . In the present study, we have determined the effects of rasagiline, its S-optical isomer TVP1022 and their metabolite, aminoindan (devoid of propargylamine moiety), and propargylamine itself on the regulation of APP processing and the signaling pathways that are involved, using cultured human SH-SY5Y neuroblastoma and rat phaeochromocytoma PC12 cells. Moreover, studies on the structure-activity relationship were conducted to assess whether the mechanism of these actions are attributed to the propargylamine moiety in the molecule.
MATERIALS AND METHODS

Materials
Rasagiline, propargylamine, the structurally related compounds, and the metabolite, aminoindan, (TVP136) were kindly donated by Teva Pharmaceutical Israel, Ltd. Electrophoresis reagents were obtained from Invitrogen Corporation (Carlsbad, CA). GF109203X and PD98059 were obtained from Calbiochem (LaJolla, CA), dissolved (1×100) in dimethyl sulfoxide and stored at -20°C. Tissue culture reagents were from Beth-Haemek (Israel). All other chemicals were from Sigma Chemical (St. Louis, MO). Monoclonal antibodies (MAbs) 22C11 (to APP N terminus) were purchased from Boehringer Mannheim Roche Molecular Biochemicals (Mannheim, Germany), and 6E10 (which recognize an epitope within residues 1-17 of Aβ domain of APP) was from Senetek (St. Louis MO). Anti-phospho-MAPK and anti-MAPK antibodies were purchased from Cell Signaling Technology (MA). Ro31-9790 was a kind gift from Roche Discovery (Welwyn Garden City, UK). Aβ was purchased from Bachem (Bubendorf, Switzerland).
Cell culture and experimental treatments
In this study, which is the continuation of our previous studies with the derivative of rasagiline, TV3326 (17), we used two different neuronal cell lines, the rat PC-12 and the human neuroblastoma SH-SY5Y cells. Both cell lines have been widely used for neurological and neurochemical studies involving APP regulation because they constitutively express significant levels of APP and release considerable amounts of nontoxic, nonamyloidogenic soluble APPα. SH-SY5Y human neuroblastoma cells were plated in 100-mm culture dishes and cultured in Dulbecco's modified Eagle's medium (DMEM) (4500 mg/l glucose) containing 10% fetal calf serum (FCS) and a mixture of 1% penicillin/streptomycin/nystatin. PC12 cells, originated from rat pheochromocytoma, were grown to confluence in T75 flasks containing DMEM (1000 mg/l glucose) and supplemented with 5% FCS, 10% horse serum, and a mixture of 1% pencillin/streptomycin/nystatin. Cell cultures were incubated at 37°C in humid 5% CO 2 /95% air environment.
For the experiments, cells were seeded (2×10 6 ) onto 100-mm plates (for SH-SY5Y cells) or T75 flasks (for PC12 cells) in culture medium supplemented with full serum for 48 h. The cells were replaced with fresh medium containing 0.5% FCS for an additional 24 h (subconfluent culture), and then the experiments were performed in fresh medium containing 0.5% FCS for the indicated time periods at 37°C. After incubation with various drugs, the conditioned media were collected, centrifuged at 3500g (10 min, 4°C) to remove cell debris, and the cleared supernatants were concentrated 10-fold by lyophilization. In addition, neuronal cell injury was evaluated by morphological characteristics, visualized by phase-contrast microscopy.
Measurement of cell death
Determination of sAPP
Protein concentrations of cell lysates were assayed using Bradford reagent (Sigma Chemical). Equal amounts of volumes of conditioned medium, standardized to lysate protein, were subjected to sodium dodecyl sulfate (SDS)-nitrocellulose membranes, using either the MAbs 22C11 or 6E10 in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, containing 0.05% Tween 20 and 1% bovine serum albumin (BSA). Immunoreactivity was detected using anti-mouse IgG-conjugated with horseradish peroxidase and an enhanced chemiluminescence method (Amersham, Pharmacia Biotech, UK). Blots were developed for different times to span a linear range of response, and the relative intensity of immunoreactive bands on the exposed films was quantified by computerassisted densitometry program (Quantity One, Bio-Rad, Hercules, CA).
Extracellular signal-regulated kinase (ERK) activity
The kinase activity of the ERKs was measured using the MAPK assay kit (Cell Signaling Technology) according to the manufacturer's protocol. In brief, for kinase activity assays, PC12 cells were grown in 6-well plates (5×10 5 cells/well). Eighteen to twenty-four hours before experiments, the medium was replaced with DMEM with 0.5% FCS and treated as described in the figures. Experimental treatments were performed in 1 ml medium containing 0.5% FCS, with the vehicle or test drugs and/or inhibitors at 37°C, as described in the figures. After treatment, reactions were stopped by placing cells on ice and aspirating the medium. Cells were harvested in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 1% Triton X-100, and protease-and phosphatase-inhibitor cocktails. Protein concentration was determined by the Bradford method. As described previously (17) , each cell lysate, containing 30 µg protein, was separated on 4-12% SDS-polyacrylamide electrophoresis gels, immunoblotted, and identified using phospho-p44/42 MAPK (Thr202/Tyr204) antibody or p44/42 MAPK antibody. Data are representative of three to six independent experiments.
RESULTS
Neuroprotective effect of rasagiline against Aβ 1-42 toxicity
Because Αβ peptides have been shown by several studies to be highly toxic in a variety of primary neurons and neuronal cell lines, we characterized the response of PC-12 cells to Αβ 1-42 , using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, as described previously (17) . Treatment of PC-12 cells with Αβ 1-42 (1-50 µM) for 24 h caused a dose-dependent loss of cell viability being maximal at 10 µM Αβ 1-42 (data not shown).
Previous studies have shown that rasagiline exhibits neuroprotective and antiapoptotic activity against several neurotoxins (2) . To evaluate whether rasagiline could also prevent Aβ-induced toxicity, we preincubated rat PC12 neuronal cells for 1 h with rasagiline (1 and 10 µM), followed by 24-h treatment with aggregated Aβ 1-42 (10 µM), and cell death was assessed by Trypan blue exclusion (Fig. 1A ) by an apoptotic cell death detection ELISA (Fig. 1B) and by morphological characteristics visualized by phase-contrast microscopy ( Fig. 1C) . Figure 1 shows that Aβ 1-42 markedly reduced cell viability (~66% of control), whereas rasagiline significantly protected (P<0.05) PC12 cells against Aβ 1-42 neurotoxicity.
Rasagiline alone (1 and 10 µM) also induced a significant improvement in PC12 cell viability, which is presumably due to its effect on cell survival after serum reduction and withdrawal (19) . We have recently studied this effect of rasagiline in detail (in preparation). In addition, using the ELISA detection assay, we found that the S-isomer of rasagiline, TVP1022 (1 and 10 µM), which is not an MAO inhibitor, also decreased the percentage of cell death from 142 ± 5% to 108 ± 7% and 91 ± 11%, indicating that MAO inhibition is not a prerequisite for neuroprotection (data not shown).
Effect of rasagiline and its derivatives on sAPPα processing
Recently, we have reported that TV3326, which was synthesized from rasagiline for the treatment of AD, stimulates the release of sAPPα (17) . In the present study, we determined whether rasagiline and other propargylamine-containing drugs also regulate APP processing. Table 1 demonstrates that the propargylamine-containing compounds, TV3326 and its S-isomer TV3279, rasagiline and its S-isomer TVP1022, and selegiline, significantly induced sAPPα release.
We further characterized, in detail, the effect of rasagiline on APP processing and the signaling pathways that are involved. Figure 2 shows that treatment of SH-SY5Y neuroblastoma cells for 3 h with increasing concentrations of rasagiline resulted in a significant dose-dependent increase in sAPPα released into the medium, compared with the level in control, untreated cells. The maximal effect was obtained at a concentration of 10 µM, which resulted in a ~3.0-fold increase in sAPPα secretion over the basal levels. PC12 cells treated for 3 h with various doses of rasagiline also showed a concentration-dependent release of sAPPα (Fig. 3) . The maximal stimulation effect being observed again at the concentration of 10 µM. Because α-secretase is a zinc metalloproteinase, susceptible to inhibition by hydroxamate-based compounds, we examined the effect of the hydroxamic acid-based metalloprotease, Ro31-9790, on rasagilinemediated sAPPα release. As shown in Figure 4A , pretreatment of PC12 cells with 100 µM Ro31-9790 blocked rasagiline-enhanced cleavage of sAPPα. Thus, these findings demonstrate that rasagiline affects APP processing by activating Ro31-9790-sensitive metalloprotease(s), further suggesting that its effect was mediated via α-secretase activity.
In previous studies, we demonstrated that TV3326 modulated the release of sAPPα by MAPK and PKC-dependent mechanisms (17) . Similar to TV3326, rasagiline-induced sAPPα release was significantly reduced by the MAPK kinase (MEK) inhibitor PD98059 (30 µM) and by the PKC inhibitor GF109203X (2.5 µM) (Fig. 4B, 4C ). These results suggest the involvement of MAPK-and PKC-dependent pathways also in rasagiline-stimulated sAPPα secretion.
Activation of MAPK by rasagiline
Rasagiline, dose dependently, increased the immunoreactivity of the phosphorylated MAPK in PC12 cells (Fig. 5A ) but had no effect on total levels of MAPK proteins. Activation occurred with doses as low as 0.1 µM of rasagiline and maximal activation at 10 µM. To determine the inhibitory potential of a noncompetitive inhibitor of MEK phosphorylation and activation, the effect of PD98059 on rasagiline-induced phosphorylation of MAPK was examined. Pretreatment with PD98059 (30 µM) blocked the rasagiline-induced increase of MAPK phosphorylation (Fig.  5B) . We also examined the role of PKC signaling pathway in rasagiline-stimulated MAPK activation, using the specific PKC-inhibitor GF109203X (2.5 µM). Preincubation with GF109203X abolished the effect of rasagiline on MAPK activation (Fig. 5B) , suggesting the involvement of PKC in rasagiline-induced MAPK activation.
Effects of propargylamine on sAPPα processing and MAPK activation
To determine the role of the propargyl moiety in the aforementioned drugs on APP processing, the effects of propargylamine on sAPPα release and MAPK activation were assessed. Figure 6A , 6B shows that treatment of SH-SY5Y neuroblastoma and PC12 cells with increasing concentrations of propargylamine resulted in a significant, dose-dependent increase in sAPPα into the medium, compared with the level in control, untreated cells. The maximal effect was obtained at a concentration of 10 µM. Furthermore, based on immunoblot analysis with antiphospho-p44/p42, propargylamine, dose dependently, induced MAPK phosphorylation in PC12 cells (Fig. 7) . These findings indicate that the effects of propargylamine on both sAPPα release and MAPK activation are similar to those of rasagiline, TV3326, and TV3279. However, the metabolite of rasagiline, aminoindan (TVP136), that lacks the propargyl group, did not show such effects on either sAPPα release (Table 1) or MAPK activation (data not shown).
DISCUSSION
In the present study, we show for the first time, that the anti-Parkinson-propargylaminecontaining MAO-B inhibitor drug, rasagiline, has neuroprotective properties against Aβ-induced cytotoxicity. Furthermore, our results demonstrate that rasagiline induces sAPPα release and ERK activation, and it is suggested that the mechanism of action is attributed to the propargylamine moiety in the molecule.
Rasagiline has been shown to have potent neuroprotective-antiapoptotic activity in PC-12 cells deprived of serum and NGF (20) and against endogenous neurotoxin N-methyl-R-salsolinol (7, 8, 20) ; 6-hydroxydopamine (21); SIN-1, a peroxynitrite donor (6); glutamate toxicity in rat hippocampal primary neurons (22) ; and in several in vivo models, including N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), global ischaemia, and closed head injury (23, 24) . The antiapoptotic action of the drug is dependent on synthesis of new proteins, which are prevented by the transcriptional and translational inhibitors cycloheximide and actinomycin, respectively, in partially neuronally differentiated PC12 cells (25) . The mechanism of the antiapoptotic effect of rasagiline against these neurotoxins and the identity of the antiapoptotic proteins synthesized have been shown to be related to the ability of rasagiline to enhance the expression of the antiapoptotic Bcl-2 and Bcl-x L in neuroblastoma SH-SY5Y cells (26) . In addition, rasagiline prevented the neurotoxins (SIN-1 and N-methyl-R-salsolinol)-induced fall in mitochondrial membrane potential (∆Ψm) (6, 8) and opening of the mitochondrial transition pore, which is part of the voltage-dependent anion channel (VDAC) (7) . Indeed, here we demonstrate that Aβ 1-42 -induced cytotoxicity in PC12 cells is prevented by rasagiline pretreatment. Aβ, similar to other neurotoxins (e.g., SIN-1), causes the fall in ∆Ψm (27, 28) , initiates the opening of mitochondrial transition pore (29, 30) , releases cytochrome c (27) , and causes alteration in calcium buffering at VDAC (31) . Thus, as has been previously demonstrated, rasagiline protects not only cell viability but also cell function (9, 32).
However, it is unlikely that its neuroprotective effect is related to MAO-B inhibition, because PC12 cells contain MAO type A rather than type B (33) and the range of concentrations used in this study is not sufficient to inhibit MAO-A (1, 3) . Moreover, the S-isomer of rasagiline, TVP1022, which is not an inhibitor of MAO-A or of -B (1, 3) , also protected PC12 cells from Aβ-evoked apoptosis, suggesting that the mode of action is independent of MAO inhibition. These results are consistent with previous reports providing clear evidence that the neuroprotection by rasagiline and its derivatives does not depend on inhibition of MAO-B (3) but rather is associated with some intrinsic pharmacological action of the propargyl moiety in these compounds acting on the mitochondria cell survival proteins (32).
We have recently described several bifunctional novel carbamate-containing analogs of rasagiline, TV3326 and TV3279, by combining ChE and MAO inhibitory activities in one molecule as a potential treatment for AD (34, 35) . These drugs potently stimulated the release of the nonamyloidogenic α-secretase form of sAPP by PKC-and MAPK-dependent pathways (17) . Thus, a major aim of this study was to determine whether rasagiline, a noncholinergic drug, similar to its cholinesterase inhibitor derivatives, TV3326 and TV3279 (14) , can also regulate APP processing and to investigate the signaling pathways that are involved in its action. In our investigation we have observed that short treatment (3 h) with rasagiline can affect APP metabolism by stimulating sAPPα release in SH-SY5Y neuroblastoma and PC12 cells. Increased sAPPα secretion was detected by the mAb 22C11, as well as by the mAb 6E10, which recognizes α-secretase-cleaved APP (36) . The increase was dose-dependent and the stimulatory effect of rasagiline on sAPPα secretion was inhibited by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, indicating that the effect was mediated via α-secretase processing. The use of hydroxamate-based inhibitors has previously allowed the isolation and purification of the TNF-α converting enzyme (TACE), a member of the ADAM (a disintegrin and metalloprotease) subgroup of the metzincin family of proteases, and recent reports have implicated TACE or ADAM-17 and ADAM-10 as candidate α-secretase(s) (37). Thus, rasagiline affects APP metabolism by increasing the α-secretase processing pathway and thereby could be beneficial for the treatment of AD by shifting the balance of APP processing toward a presumably nonpathogenic pathway.
Indeed, the proportion of APP, processed by α-secretase vs. β-secretase, may affect the amount of the amyloid fragments, for example, mutations in APP, found in a Swedish familial AD pedigree map to the β-secretase cleavage site in APP and favor β-secretase cleavage of APP (38) . In these studies, cells expressing the mutations secrete increased amounts of Aβ, as compared with cells expressing wild-type APP. In contrast, activation of PKC by PMA was shown to favor α-secretase, nonamyloidogenic cleavage at the expense of β-secretase cleavage (39) . Moreover, transgenic mice engineered to produce high levels of Aβ have decreased levels of brain Aβ following PMA treatment (40) . Therefore, it is apparent that stimulation of α-secretase cleavage may be a useful intervention to influence the production of nondeleterious and even beneficial sAPPα and, at the same time, reduce the relative amounts of Aβ peptides. Additional studies strongly suggest that the nonamyloidogenic sAPPα has potent neurotrophic and neuroprotective activities against excitotoxic and oxidative insults in various cellular models, and it was shown to confer resistance against p53-mediated apoptosis (41, 42) . Therefore, it can be suggested that sAPPα, derived from rasagiline-mediated APP processing, can serve as a neuroprotective agent against the toxic activity of Aβ.
Among the mechanisms that regulate proteolytic APP processing, activation of PKC and PKCcoupled receptors was shown to increase the generation of sAPP derived by α-secretase cleavage. In addition, it was suggested that the MAPK signaling pathway mediates both PKC and tyrosine kinase receptor regulation of APP catabolism (43, 44) . The data presented here demonstrate that sAPPα release, induced by rasagiline, was modulated by inhibitors of PKC and the ERK MAPK signaling pathway. Moreover, in results complementary to the inhibitor studies, we found that rasagiline dose dependently increased the immunoreactivity of the phosphorylated MAPK in PC12 cells. Western blot analysis, using a phosphospecific MAPK antibody, revealed a concentration-dependent (0.1-10 µM) increase in MAPK phosphorylation in cells stimulated with rasagiline. The MEK inhibitors, PD98059, antagonized MAPK activation, indicating that MEK phosphorylates MAPK in the presence of rasagiline. The specific PKC inhibitor, GF109203X, which indicated the dependence on PKC signaling pathway activity, also effectively attenuated activation of MAPK.
In conclusion, because in this study we demonstrate that rasagiline, TVP1022, and propargylamine (that lacks cholinergic activity) stimulated sAPPα release and MAPK phosphorylation, it is suggested that these effects, recently found also for TV3326, a rasagilinederivative, ChE/MAO inhibitor (43, 44) , do not appear to result from ChE-inhibitory activities. Furthermore, by comparing the actions of rasagiline with those of its S-isomer, TVP1022, which is at least 1000-fold weaker as an inhibitor of MAO (3), we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either the neuroprotection effect against Aβ toxicity or the sAPPα-induced release. Indeed, the structure-activity relationship among rasagilinerelated compounds, suggests the crucial role of the propargyl moiety on these molecules for processing of APP, because propargylamine itself induced the secretion of the nonamyloidogenic α-secretase form of the sAPP into the conditioned media of SH-SY5Y neuroblastoma and PC12 cells and significantly increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives. Following the preincubation, the cells were treated without or with rasagiline (10 µM) for 3 h. Proteins released into the conditioned media of PC12 cells were collected and analyzed for sAPP as described in Materials and Methods. The experiment is representative of three independent experiments. concentrations of propargylamine. Aliquots of cell lysates were then subjected to immunoblot analysis and probed with anti-phospho-MAPK (top blots) and anti-MAP kinase (bottom blots). Quantification of the phospho-MAPK blots were normalized using the total MAPK blots. Data are mean ± SE values of (n=3). **P<0.001 vs. control.
